Evidence map›Paper›PMID 24772092›Full record

ReviewFrontiers in physiology2014

Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow.

Natasha M Rogers, Franziska Seeger, Elsa D Garcin, David D Roberts, Jeffrey S Isenberg

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. International journal of molecular sciences · 2021
    Article
  5. Application of Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2021
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Natasha M RogersDepartment of Medicine, Vascular Medicine Institute, University of Pittsburgh School of Medicine Pittsburgh, PA, USA.
Franziska SeegerDepartment of Chemistry and Biochemistry, University of Maryland Baltimore County Baltimore, MD, USA.
Elsa D GarcinDepartment of Chemistry and Biochemistry, University of Maryland Baltimore County Baltimore, MD, USA.
David D RobertsLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH Bethesda, MD, USA.
Jeffrey S IsenbergDepartment of Medicine, Vascular Medicine Institute, University of Pittsburgh School of Medicine Pittsburgh, PA, USA ; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine Pittsburgh, PA, USA.
University of Maryland, Baltimore County · USUniversity of Pittsburgh · USCenter for Cancer Research · US

Funding

Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLADWIN, MARK T · 2011 to 2020
$26.1M
Cellular Interactions with ThrombospondinZIASC009172 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI ROBERTS, DAVID D · 2009 to 2024
$17.9M
Roles of Glycoconjugates and Redox Signaling in Tumor BiologyZIASC009174 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI ROBERTS, DAVID D · 2009 to 2024
$4.9M
Bioengineering Tracheas Through Targeting Activated CD47R21EB017184 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BADYLAK, STEPHEN F. · 2014 to 2015
$423k
NHLBI NIH HHS P01 HL103455NIBIB NIH HHS R21 EB017184
6 · The paper itself

Abstract

Nitric oxide (NO) maintains cardiovascular health by activating soluble guanylate cyclase (sGC) to increase cellular cGMP levels. Cardiovascular disease is characterized by decreased NO-sGC-cGMP signaling. Pharmacological activators and stimulators of sGC are being actively pursued as therapies for acute heart failure and pulmonary hypertension. Here we review molecular mechanisms that modulate sGC activity while emphasizing a novel biochemical pathway in which binding of the matricellular protein thrombospondin-1 (TSP1) to the cell surface receptor CD47 causes inhibition of sGC. We discuss the therapeutic implications of this pathway for blood flow, tissue perfusion, and cell survival under physiologic and disease conditions.

Indexed as

cardiovascular diseaseCD47cyclic guanosine monophosphatenitric oxideROSsoluble guanylate cyclasethrombospondin-1

Identifiers

PMID24772092
PMCPMC3983488
OpenAlexW2036237867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.